According to Novocure
's latest financial reports the company's current revenue (TTM ) is HK$4.87 Billion. In 2024 the company made a revenue of HK$4.69 Billion an increase over the revenue in the year 2023 that were of HK$3.97 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2025 (TTM) | HK$4.83 B | 2.96% |
2024 | HK$4.69 B | 18.12% |
2023 | HK$3.97 B | -5.34% |
2022 | HK$4.20 B | 0.73% |
2021 | HK$4.17 B | 8.86% |
2020 | HK$3.83 B | 40.07% |
2019 | HK$2.73 B | 40.85% |
2018 | HK$1.94 B | 40.45% |
2017 | HK$1.38 B | 115.18% |
2016 | HK$0.64 B | 150.64% |
2015 | HK$0.25 B |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
![]() Novocure
NVCR | HK$4.87 B | 0.00% | Jersey |
![]() Novavax NVAX | HK$9.53 B | 95.37% | ๐บ๐ธ USA |
![]() Organovo ONVO | HK$1.13 M | -99.98% | ๐บ๐ธ USA |
![]() Orchard Therapeutics
ORTX | HK$0.17 B | -96.49% | ๐ฌ๐ง UK |